Yahoo Web Search

Search results

1. pubmed.ncbi.nlm.nih.gov › 33577729Enfortumab Vedotin in Previously Treated Advanced Urothelial ...

   pubmed.ncbi.nlm.nih.gov › 33577729

   Mar 25, 2021 · Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor. (Funded by Astellas Pharma US and Seagen; EV-301 Clinica ….

   • Enfortumab Vedotin and Pembrolizumab in Untreated Advanced ...

     Methods: We conducted a phase 3, global, open-label,...

2. www.nejm.org › doi › fullEnfortumab Vedotin in Previously Treated Advanced Urothelial ...

   www.nejm.org › doi › full

   Feb 12, 2021 · EV-301 was a global, open-label, phase 3 trial that evaluated enfortumab vedotin as compared with chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had...

   • Author: Thomas Powles, Jonathan E Rosenberg, Guru P Sonpavde, Yohann Loriot, Ignacio Durán, Jae-Lyun Lee, No...

   • Publish Year: 2021

3. www.nejm.org › doi › fullEnfortumab Vedotin and Pembrolizumab in Untreated Advanced ...

   www.nejm.org › doi › full

   Mar 6, 2024 · The EV-302 trial showed a significant and clinically meaningful benefit of enfortumab vedotin and pembrolizumab over chemotherapy with respect to progression-free survival and overall survival...

4. pubmed.ncbi.nlm.nih.gov › 38446675Enfortumab Vedotin and Pembrolizumab in Untreated Advanced ...

   pubmed.ncbi.nlm.nih.gov › 38446675

   Mar 7, 2024 · Methods: We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

5. www.urotoday.com › recent-abstracts › urologicEnfortumab Vedotin in Previously Treated Advanced Urothelial ...

   www.urotoday.com › recent-abstracts › urologic

   • Cached

   Feb 12, 2021 · Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy, patients with locally advanced or metastatic urothelial carcinoma, EV-301 Clinical Trial, platinum-based treatment and a PD-1 or PD-L1 inhibitor.

6. ascopubs.org › doi › 10Primary results of EV-301: A phase III trial of enfortumab ...

   ascopubs.org › doi › 10

   Mar 2, 2021 · Enfortumab vedotin (EV) is an antibody-drug conjugate directed to Nectin-4, a cell adhesion molecule highly expressed in urothelial carcinoma, with remarkable efficacy observed in a single-arm trial in this setting. This randomized phase III study (EV-301) was performed to confirm these findings.

7. europepmc.org › article › MEDEnfortumab Vedotin in Previously Treated Advanced Urothelial ...

   europepmc.org › article › MED

   • Cached

   Feb 12, 2021 · EV-301 is a global, open-label, phase 3 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma who had previously received a platinum-containing chemotherapy and experienced disease progression during or following treatment with a PD-1/L1 inhibitor.